Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-10-2014 | Review Article

Inventory of economic evaluation of head and neck oncology from the German perspective

Authors: Thiemo Kurzweg, R. Knecht

Published in: European Archives of Oto-Rhino-Laryngology | Issue 10/2014

Abstract

New treatment strategies for head and neck neoplasms include induction chemotherapy and biomarker treatment. Moreover, different therapeutic modalities, especially robotic surgery, induction chemotherapy, biotherapy and altered fractionation schedules of chemo-(radio)therapy are newly combined to optimize treatment benefit and minimize treatment-associated morbidity. Often, overall survival does not change significantly between the competing treatment schedules. Therefore, the evaluation of the patient’s treatment-related quality of life (QoL) and organ function becomes more and more important. Finally, the sponsor’s financial resources are restricted, which makes it necessary to evaluate therapies for pricing and effectiveness. In head and neck cancer in Europe, analyses of the current situation are lacking. Selective literature research for publications on economic cost-effectiveness analyses was performed. An overview of the current situation with a special focus on Europe is provided. Cost-effectiveness values and QoL assessments should be respected in former prospective study construction to gain systematic information on this topic.

§ 12, SGB V, Abs. 1, German Social Security Code.

Feng Y, Wang B, Wen S (2011) Laser surgery versus radiotherapy for T1–T2N0 glottic cancer: a meta-analysis. ORL J Otorhinolaryngol Relat Spec 73(6):336–342PubMedCrossRef

Higgins KM (2011) What treatment for early-stage glottic carcinoma among adult patients: CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is superior in terms of cost utility? Laryngoscope 121(1):116–134PubMedCrossRef

Cragle SP, Brandenburg JH (1993) Laser cordectomy or radiotherapy: cure rates, communication, and cost. Otolaryngol Head Neck Surg 108(6):648–654PubMed

Merrot O, Bige V, Poupart M, Montbarbon X, Ardiet JM, Pignat JC (2010) Comparison between external radiotherapy and laser microsurgery for the treatment of TisT1N0 glottic carcinoma: clinical modelling and cost-minimization study from the French national health insurance payer’s point of view. Rev Laryngol Otol Rhinol (Bord) 131(4–5):257–262

Morton RP (1997) Laryngeal cancer: quality-of-life and cost-effectiveness. Head Neck 19(4):243–250PubMedCrossRef

Leon X, Quer M, Orus C, Lopez-Pousa A, Pericay C, Vega M (2000) How much does it cost to preserve a larynx? An economic study. Eur Arch Otorhinolaryngol 257(2):72–76PubMedCrossRef

Davis GE, Schwartz SR, Veenstra DL, Yueh B (2005) Cost comparison of surgery vs organ preservation for laryngeal cancer. Arch Otolaryngol Head Neck Surg 131(1):21–26PubMedCrossRef

van Agthoven M, Heule-Dieleman HA, Knegt PP et al (2006) Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol 263(8):729–737PubMedCrossRef

Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP (2009) Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 31(10):1255–1262PubMedCrossRef

10.

Brown B, Diamantopoulos A, Bernier J et al (2008) An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 11(5):791–799PubMedCrossRef

11.

Bagust A, Greenhalgh J, Boland A et al (2010) Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. PharmacoEconomics 28(6):439–448PubMedCrossRef

12.

Greenhalgh J, Bagust A, Boland A et al (2009) Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol Assess 13(Suppl 3):49–54PubMed

13.

Fountzilas G, Papakostas P, Dafni U et al (2006) Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 17(10):1560–1567PubMedCrossRef

14.

Hopper C, Niziol C, Sidhu M (2004) The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 40(4):372–382PubMedCrossRef

15.

Kubler A, Niziol C, Sidhu M, Dunne A, Werner JA (2005) Analysis of cost effectiveness of photodynamic therapy with Foscan (Foscan-PDT) in comparison with palliative chemotherapy in patients with advanced head-neck tumors in Germany. Laryngorhinootologie 84(10):725–732PubMedCrossRef

16.

Aviv JE, Sataloff RT, Cohen M et al (2001) Cost-effectiveness of two types of dysphagia care in head and neck cancer: a preliminary report. Ear Nose Throat J 80(8):553–6–558

17.

Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL (2004) Economic burden of head and neck cancer. A literature review. Eur J Health Econ HEPAC Health Econ Prev Care 5(1):70–80CrossRef

18.

Drummond MF, Mason AR (2007) European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Onc 25(2):191–195CrossRef

19.

Selke B, Allenet B, Bercez C, Bogillot O, Lebrun T, Lefebvre JL (2001) Economic assessments of head and neck cancers: a review. Bull Cancer 88(8):759–764PubMed

20.

Kirschneck M, Sabariego C, Singer S, Tschiesner U (2013) Assessment of functional outcomes in patients with head and neck cancer according to the International Classification of Functioning, Disability and Health Core Sets from the perspective of the multi-professional team: Results of 4 Delphi surveys. Head Neck. doi:10.1002/hed.23399 [Epub ahead of print]

Title: Inventory of economic evaluation of head and neck oncology from the German perspective
Authors: Thiemo Kurzweg
R. Knecht
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Oto-Rhino-Laryngology / Issue 10/2014
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-013-2878-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inventory of economic evaluation of head and neck oncology from the German perspective

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2014

Biofilms in chronic rhinosinusitis with polyps: is eradication possible?

The sino-nasal outcome test (SNOT)-22: validation for Greek patients

The effect of temperature on basal tension and thyroarytenoid muscle contraction in an isolated rat glottis model

Gentamicin conditioning confers auditory protection against noise trauma

The up-regulation expression of APRIL is a marker of glottic malignant disease

Vasospasm of labyrinthine artery in cerebellopontine angle surgery: evidence brought by distortion-product otoacoustic emissions